AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10972631
Drug: Deferred simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Deferred simvastatin treatment (40 mg/d after 3 months if LDL-C >3.0 mmol/L)
Trial: 10972631
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (immediate and deferred simvastatin treatment)
Trial: 1574970
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of naloxone 1 microgram kg‐1 h‐1
Trial: 4019017
Drug: Group D
RxNorm normalized name: Prostaglandin group D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group D (30 min of daily self‐selected aerobic activity)
Trial: 31320980
Drug: Antioxidant cocktail
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant cocktail (AOC) - 1,000 mg vitamin C, 600 IU vitamin E, and 600 mg α-lipoic acid
Trial: 26352063
Drug: Low-dose dopamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dopamine (3 μg/kg/min)
Trial: 26352063
Drug: Medium-dose dopamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-dose dopamine (5 μg/kg/min)
Trial: 12131261
Drug: Reboxetine 2
RxNorm normalized name: REBOXETINE
DrugBank: Reboxetine (DB00234)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reboxetine 2 x 4 mg (REB)
Trial: 10421596
Drug: Ibutilide fumarate
RxNorm normalized name: Ibutilide Fumarate
DrugBank: Ibutilide (DB00308)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ibutilide fumarate 0.25 mg
Trial: 10421596
Drug: Ibutilide fumarate
RxNorm normalized name: Ibutilide Fumarate
DrugBank: Ibutilide (DB00308)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ibutilide fumarate 0.5 mg
Trial: 10421596
Drug: Ibutilide fumarate
RxNorm normalized name: Ibutilide Fumarate
DrugBank: Ibutilide (DB00308)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ibutilide fumarate 1.0 mg
Trial: 8678066
Drug: Erythropoietin (EPO)
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (EPO) treatment in elderly patients
Trial: 8678066
Drug: Erythropoietin (EPO)
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (EPO) treatment in younger patients
Trial: 6606554
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (four times 0.5 g/d)
Trial: 26589368
Drug: atorvastatin (10mg/day)
RxNorm normalized name: atorvastatin 10 MG
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: atorvastatin (10mg/day)
Trial: 24706353
Drug: Prophylactic medication
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic medication (brimonidine and timolol) instilled 5 minutes before injection
Trial: 24706353
Drug: No prophylactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No prophylactic medication
Trial: 24706353
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (with and without prophylactic medication)
Trial: 20595646
Drug: n‐3 group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n‐3 group (2.5 g/d of n‐3 LCPUFA, with 1.67 g of EPA and 0.83 g of DHA)
Trial: 15660732
Drug: Nateglinide 120
RxNorm normalized name: nateglinide 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nateglinide 120 mg (t.i.d., n = 33)
Trial: 15660732
Drug: Nateglinide 120
RxNorm normalized name: nateglinide 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nateglinide 120 mg (t.i.d.)
Trial: 31522849
Drug: Peanut-0 group
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peanut-0 group (4000 mg peanut protein through to week 104, then discontinued)
Trial: 31522849
Drug: Peanut-300 group
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peanut-300 group (4000 mg peanut protein through to week 104, then 300 mg daily for 52 weeks)
Trial: 24344787
Drug: Transdermal fentanyl
RxNorm normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Transdermal fentanyl solution (TFS) 2.7 mg/kg applied 2-4 hours prior to surgery
Trial: 24344787
Drug: Oxymorphone hydrochloride
RxNorm normalized name: Oxymorphone Hydrochloride
DrugBank: Oxymorphone (DB01192)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxymorphone hydrochloride 0.22 mg/kg administered subcutaneously 2-4 hours prior to surgery and every 6 hours for 90 hours
Trial: 19597964
Drug: Treatment Outcome
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment Outcome Score (TOS)
Trial: 12407029
Drug: i.v. human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. human albumin administration
Trial: 7544439
Drug: Adenoviral vector
RxNorm normalized name: Adenoviral vector-RheoSwitch Therapeutic System-human interleukin 12
DrugBank: Ad-RTS-hIL-12 (DB17177)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenoviral vector containing normal CFTR cDNA (doses: 1, 10, 100, 1000)
Trial: 7544439
Drug: Adenoviral vector
RxNorm normalized name: Adenoviral vector-RheoSwitch Therapeutic System-human interleukin 12
DrugBank: Ad-RTS-hIL-12 (DB17177)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenoviral vector (highest dose)
Trial: 7544439
Drug: Lower doses
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower doses of adenoviral vector
Trial: 367570
Drug: BOPP (4-drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BOPP (4-drug regimen)
Trial: 367570
Drug: MOPP (4-drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOPP (4-drug regimen)
Trial: 367570
Drug: BOP (3-drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BOP (3-drug regimen)
Trial: 367570
Drug: OPP (3-drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPP (3-drug regimen)
Trial: 367570
Drug: Maintenance chemotherapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance chemotherapy (vinblastine, chlorambucil, or chlorambucil plus monthly vincristine + prednisone)
Trial: 367570
Drug: 4-drug programs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-drug programs (BOPP and MOPP)
Trial: 28246176
Drug: Intralipid postconditioning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralipid postconditioning (ILPC) group received an intravenous infusion of 20% intralipid (2 mL/kg) just 10 min before aortic cross‐unclamping
Trial: 22998737
Drug: Weight loss
RxNorm normalized name: HERBAL WEIGHT LOSS AID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight loss and decreased fasting insulin
Trial: 17966842
Drug: Insulin therapy
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin therapy for 5 weeks
Trial: 7528485
Drug: 60 mg/d
RxNorm normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/d of carbimazole
Trial: 7528485
Drug: Minimal dose
RxNorm normalized name: Centipeda minima whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal dose required to obtain euthyroidism (low dose)
Trial: 7528485
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose (60 mg/d)
Trial: 31901245
Drug: Strict glycemic
RxNorm normalized name: Euphrasia stricta extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strict glycemic control (target BG 80-120 mg/dL)
Trial: 31901245
Drug: Conventional glycemic
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional glycemic control (target BG 180-200 mg/dL)
Trial: 25219423
Drug: 6-month weekly
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-month weekly group intervention plus six monthly maintenance sessions (N=104)
Trial: 16532466
Drug: Oxybutynin transdermal
RxNorm normalized name: oxyBUTYnin Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxybutynin transdermal patch
Trial: 3095220
Drug: Lysine aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lysine aspirin (150, 300, 600 mg)
Trial: 3095220
Drug: Soluble aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble aspirin (150, 300, 600 mg)
Trial: 3095220
Drug: Conventional aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional aspirin (150, 300, 600 mg)
Trial: 29705075
Drug: Single injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection femoral nerve block (sFNB)
Trial: 22402472
Drug: Watermelon extract
RxNorm normalized name: watermelon extract 50 MG/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Watermelon extract supplementation (L‐citrulline/L‐arginine, 6 g daily)
Trial: 16476804
Drug: Pyridostigmine bromide
RxNorm normalized name: Pyridostigmine Bromide
DrugBank: Pyridostigmine (DB00545)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pyridostigmine bromide 60 mg
Trial: 16476804
Drug: Pyridostigmine bromide
RxNorm normalized name: Pyridostigmine Bromide
DrugBank: Pyridostigmine (DB00545)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pyridostigmine bromide 60 mg and midodrine hydrochloride 5 mg
Trial: 10988016
Drug: Lovastatin 20-40
RxNorm normalized name: lovastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin 20-40 mg daily
Trial: 1645103
Drug: Alcohol (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0 to 1.0 g/kg) administered alone
Trial: 1645103
Drug: Cocaine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine (4 to 96 mg/70 kg) administered alone
Trial: 1645103
Drug: Cocaine and
RxNorm normalized name: Cocaine and morphine only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine and alcohol administered in combination
Trial: 2409325
Drug: High-dose methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methotrexate (HD-MTX), adriblastine (ADR), and cyclophosphamide (CP) for 12 months in COSS-77.
Trial: 2409325
Drug: Doubled dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doubled dose of methotrexate (MTX), cisplatinum (CPL) or bleomycin + CP + dactinomycin (BCD) in addition to MTX and ADR for 8 months in COSS-80.
Trial: 29498170
Drug: Doxazosin (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin (8 mg/day, N = 47)
Trial: 29498170
Drug: Doxazosin (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin (8 mg/day) in T-allele carriers (CT/TT)
Trial: 29498170
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in CC genotype group
Trial: 27920083
Drug: Bedtime dosing
RxNorm normalized name: Buckley's Bedtime Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedtime dosing (BD) of enalapril (20 mg at bedtime)
Trial: 27920083
Drug: Morning dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning dosing (MD) of enalapril (20 mg in the morning)
Trial: 17460336
Drug: CHO+P+A beverage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO+P+A beverage (10 mL/kg body weight)
Trial: 17460336
Drug: CHO beverage
RxNorm normalized name: G-CSF (CHO cell derived)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO beverage (10 mL/kg body weight)
Trial: 17460336
Drug: Correlation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation with treatment differences
Trial: 9669014
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose tranexamic acid (20 mg.kg‐1)
Trial: 9669014
Drug: Medium dose
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium dose tranexamic acid (50 mg.kg‐1)
Trial: 9669014
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose tranexamic acid (100 mg.kg‐1)
Trial: 31103972
Drug: Selenium and
RxNorm normalized name: Selenium and/or selenium compound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium and anti-tuberculosis drug
Trial: 31103972
Drug: Anti-tuberculosis drug
RxNorm normalized name: Mycobacterium tuberculosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-tuberculosis drug
Trial: 19506571
Drug: Levetiracetam (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam (500 mg b.i.d. to a maximum of 1500 mg b.i.d.)
Trial: 3028596
Drug: Alternating chemotherapy
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternating chemotherapy (EVI, PAV, CMC)
Trial: 3028596
Drug: Sequential chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential chemotherapy (CAV)
Trial: 30902701
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of hormonal therapy
Trial: 27809724
Drug: Er,Cr:YSGG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Er,Cr:YSGG laser treatment (Group A)
Trial: 22088980
Drug: Clopidogrel 225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 225 or 300 mg daily
Trial: 18781341
Drug: Preoperative chemotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemotherapy (three cycles) of gemcitabine plus carboplatin or paclitaxel
Trial: 18781341
Drug: Preoperative chemotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemotherapy (three cycles) of gemcitabine plus carboplatin or cisplatin
Trial: 16046076
Drug: Betablocker (BB)
RxNorm normalized name: Dream Pure BB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betablocker (BB) propranolol 80 mg
Trial: 10751736
Drug: Ceftriaxone 100
RxNorm normalized name: ceftriaxone 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 100 mg/kg/day for 1-3 weeks
Trial: 2932742
Drug: Secnidazole (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secnidazole (2 g single oral dose)
Trial: 2932742
Drug: Tetracycline (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracycline (750 mg per day for 5 days) plus Clioquinol (1 g per day)
Trial: 30046828
Drug: CER-001, 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CER-001, 3 mg/kg, administered as 10 weekly intravenous infusions
Trial: 26945658
Drug: Levofloxacin 400
RxNorm normalized name: Levofloxacine
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin 400 mg (oral)
Trial: 26945658
Drug: Levofloxacin 400
RxNorm normalized name: Levofloxacine
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin 400 mg (oral) + Amikacin 200 mg (intravenous)
Trial: 24751903
Drug: RBV monotherapy
RxNorm normalized name: RBV
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: RBV monotherapy
Trial: 24751903
Drug: RBV combination
RxNorm normalized name: RBV
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: RBV combination therapy
Trial: 24751903
Drug: PEG‐IFNa/RBV combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐IFNa/RBV combination therapy
Trial: 22527075
Drug: Azithromycin 300
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin 300 mg/day
Trial: 20075643
Drug: Desvenlafaxine (200-400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desvenlafaxine (200-400 mg/d)
Trial: 18570573
Drug: Chest tube
RxNorm normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chest tube therapy
Trial: 11843062
Drug: Standard combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard combination therapy (genotype 2b/3a)
Trial: 9727760
Drug: Abstracts concluded
RxNorm normalized name: TITANIUM DIOXIDE 20 mg in 1 g TOPICAL STICK [Flormar Delicious Lip Stylo Sunscreen Broad Spectrum SPF 15 DS09 Delicious Abstract Melon]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abstracts concluded that the test treatment was as effective as or better than the control treatment
Trial: 9727760
Drug: Abstracts concluded
RxNorm normalized name: TITANIUM DIOXIDE 20 mg in 1 g TOPICAL STICK [Flormar Delicious Lip Stylo Sunscreen Broad Spectrum SPF 15 DS09 Delicious Abstract Melon]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abstracts concluded that the test treatment was not as effective as the control treatment
Trial: 25155105
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg on-demand udenafil
Trial: 25155105
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg once-daily udenafil
Trial: 23391421
Drug: G-CSF (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (10 μg/kg)
Trial: 17699350
Drug: Intravenous C.E.R.A.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous C.E.R.A. 0.4 microg/kg
Trial: 17699350
Drug: Subcutaneous C.E.R.A.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous C.E.R.A. 0.8 microg/kg
Trial: 10757572
Drug: Control (continued
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (continued catecholamine therapy without milrinone)
Trial: 7587035
Drug: Cefotaxime 2
RxNorm normalized name: cefotaxime 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime 2 g every 12 h
Trial: 24458836
Drug: Family-based behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-based behavioral weight loss treatment (FBT) program, 16 sessions
Trial: 19900797
Drug: Therapeutic interventions
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic interventions (excluding combination products)
Trial: 16881772
Drug: Intensive behavior
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive behavior therapy
Trial: 17667481
Drug: Prescribed medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescribed medication
Trial: 12360153
Drug: Avasimibe at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avasimibe at 50 mg daily
Trial: 12360153
Drug: Avasimibe at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avasimibe at 250 mg daily
Trial: 12360153
Drug: Avasimibe at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avasimibe at 750 mg daily
Trial: 12360153
Drug: Background lipid-lowering
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Background lipid-lowering therapy
Trial: 6794587
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg desmethyl‐diazepam
Trial: 30573355
Drug: Drink rich
RxNorm normalized name: Maltose-rich malted barley extract
DrugBank: Barley malt syrup (DB14601)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drink rich in polyphenols from red grape pomace (RGPD) - 1.562 g gallic acid equivalents (GAE)
Trial: 27776459
Drug: Plant sterols-enriched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant sterols-enriched soy milk (2.0 g free plant sterols daily)
Trial: 17245799
Drug: Weekly, monthly,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly, monthly, or occasional religious participation
Trial: 11309552
Drug: Nebivolol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol (5 mg once a day)
Trial: 2837300
Drug: Enalapril 5
RxNorm normalized name: enalapril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 5 mg twice each week
Trial: 12846491
Drug: Tamoxifen (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (administered for at least 3 years)
Trial: 2665661
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose trimethoprim
Trial: 23280432
Drug: SIT group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SIT group (specific immunotherapy)
Trial: 10582197
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium 4 mg b.i.d. (two times daily)
Trial: 10582197
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium 4 mg q.i.d. (four times daily)
Trial: 7788003
Drug: Propylthiouracil treatment
RxNorm normalized name: Propylthiouracil
DrugBank: Propylthiouracil (DB00550)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propylthiouracil treatment
Trial: 2195937
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (budesonide 200 micrograms twice a day)
Trial: 2195937
Drug: Inhaled bronchodilators
RxNorm normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled bronchodilators (terbutaline 250 micrograms, two puffs four times a day)
Trial: 2195937
Drug: Inhaled bronchodilators
RxNorm normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled bronchodilators (Group A)